Ocular Dorzolamide Nanoliposomes for Prolonged IOP Reduction: <i>in-vitro</i>and <i>in-vivo </i>Evaluation in Rabbits

Simple item page
AuthorMaryam Kouchaken
AuthorReza Bahmandaren
AuthorNeda Bavarsaden
AuthorFereydoun Farrahien
Issued Date2016-01-31en
AbstractDorzolamide ophthalmic drop is one of the most common glaucoma medications but it has a short residence time in the eye. The aim of this study is to develop ocular dorzolamide HCl nanoliposomes (DRZ – nanoliposomes) and to evaluate their potential use for the treatment of ocular hypertension. Nanoliposomes were prepared using Reverse-phase evaporation vesicle (REV) and thin layer hydration (TLH) method with 7:3 and 7:4 molar ratios of phosphatidylcholine:cholesterol. The physicochemical properties of the formulations were investigated. Formulations with 7:4 lipid ratios were evaluated in terms of drug release, physical stability and ex-vivo permeation through the excised albino rabbit cornea. The rabbits in groups of 6 were treated with selected DRZ – nanoliposomes or dorzolamide solution or marketed dorzolamid preparation (Biosopt®) and intraocular pressure (IOP) was monitored. Formulations with 7:4 molar ratio entrapped greater amount of drug compared to those with 7:3 lipid components ratio. DRZ – nanoliposomes with 7:4 lipid ratio showed more transcorneal permeation than Dorzolamide solution (pen
DOIhttps://doi.org/10.22037/ijpr.2016.1830en
URIhttps://brieflands.com/journals/ijpr/articles/125092en
KeywordOcular deliveryen
KeywordNanoliposomesen
KeywordDorzolamideen
KeywordIntraocular pressureen
KeywordCorneal permeabilityen
PublisherBrieflandsen
TitleOcular Dorzolamide Nanoliposomes for Prolonged IOP Reduction: <i>in-vitro</i>and <i>in-vivo </i>Evaluation in Rabbitsen
TypeOriginal Articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijpr-15-205.pdf
Size:
703.2 KB
Format:
Adobe Portable Document Format
Description:
Article/s PDF
Download

Collections

Iranian Journal of Pharmaceutical Research